

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-22 (cancelled)

23. (Currently Amended) A method of inhibiting binding of IL-13 to the IL-13 receptor in a mammalian subject, said method comprising administering a ~~therapeutically effective amount of a composition of claim 16~~ polypeptide encoded by a polynucleotide that hybridizes at high stringency to the complement of the portion of SEQ ID NO:3 that encodes about from about amino acid 26 to about amino acid 341 of SEQ ID NO:4,

wherein said polypeptide is administered in an amount sufficient to inhibit binding of IL-13 to the IL-13 receptor.

Claims 24-27 (cancelled)

28. (Currently Amended) A method of treating an IL-13-related condition in a mammalian subject, said method comprising administering a therapeutically effective amount of ~~a composition of claim 16~~ polypeptide encoded by a polynucleotide that hybridizes at high stringency to the complement of the portion of SEQ ID NO:3 that encodes about from about amino acid 26 to about amino acid 341 of SEQ ID NO:4, and wherein said IL-13 related condition is selected from the group consisting of an allergic condition, atopy, and asthma.

Claims 29-47 (cancelled).

48. (newly added) The method of claim 23, wherein said polypeptide comprises from about amino acid 26 to about amino acid 341 of SEQ ID NO:4.

49. (newly added) The method of claim 23, wherein said polypeptide is part of a fusion protein.

50. (newly added) The method of claim 49, wherein said fusion protein comprises an antibody fragment.

51. (newly added) The method of claim 50, wherein said antibody fragment includes an Fc fragment.

52. (newly added) The method of claim 48, wherein said polypeptide is part of a fusion protein.

53. (newly added) The method of claim 52, wherein said fusion protein comprises an antibody fragment.

54. (newly added) The method of claim 53, wherein said mammalian subject is a human.

55. (newly added) The method of claim 48, wherein said polypeptide comprises amino acids 26-341 of SEQ ID NO:4.

56. (newly added) The method of claim 28, wherein said IL-13 related condition is an allergic condition.

57. (newly added) The method of claim 28, wherein said IL-13 related condition is asthma.

58. (newly added) The method of claim 28, wherein said IL-13 related condition is atopy.

59. (newly added) The method of claim 28, wherein said polypeptide comprises from about amino acid 26 to about amino acid 341 of SEQ ID NO:4.

60. (newly added) The method of claim 28, wherein said polypeptide is part of a fusion protein.

61. (newly added) The method of claim 60, wherein said fusion protein comprises an antibody fragment.

62. (newly added) The method of claim 59, wherein said polypeptide is part of a fusion protein.

63. (newly added) The method of claim 62, wherein said mammalian subject is a human.

64. (newly added) The method of claim 57, wherein said polypeptide comprises from about amino acid 26 to about amino acid 341 of SEQ ID NO:4.

65. (newly added) The method of claim 64, wherein said polypeptide is part of a fusion protein.

66. (newly added) The method of claim 65, wherein said fusion protein comprises an antibody fragment.

Applicants: Collins et al.
U.S.S.N. 09/868,123

67. (newly added) The method of claim 66, wherein said antibody fragment includes an Fc fragment.